非酒精性脂肪性肝病与血清尿酸

徐贝贝; 王炳元

doi:10.3969/j.issn.1001-5256.2016.03.007

非酒精性脂肪性肝病与血清尿酸

DOI: 10.3969/j.issn.1001-5256.2016.03.007

中国医科大学附属第一医院老年消化科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2206
- HTML全文浏览量: 37
- PDF下载量: 499
- 被引次数: 0
出版历程
- 收稿日期: 2015-12-25
- 出版日期: 2016-03-20

Nonalcoholic fatty liver disease and serum uric acid

Department of Geriatric Gastroenterology,The First Affiliated Hospital of China Medical University

摘要

摘要: 非酒精性脂肪性肝病（NAFLD）被视为代谢综合征（MS）的肝脏表现,除糖脂代谢紊乱外,血清尿酸（SUA）的水平也左右着NAFLD的进展。叙述了两者相关的最新研究成果,指出无论健康个体或患者的SUA都能够独立预测患者MS、2型糖尿病和心血管疾病的风险,其机制可能是SUA通过诱导活性氧（ROS）增加ROS-硫氧还蛋白相互作用蛋白（TXNIP）表达,进而引发pyrin结构域蛋白3炎症小体激活和白细胞介素的分泌;无论基础或临床研究,使用降低SUA的药物可以抑制TXNIP通路,降低血糖水平,减轻肝细胞ROS、炎症、脂肪变性和纤维化。提示减少SUA可能是NAFLD一个有前途的潜在治疗方法,值得基础和临床的进一步研究。
- 脂肪肝 /
- 尿酸 /
- 代谢综合征X
Abstract: Nonalcoholic fatty liver disease( NAFLD) is considered the manifestation of metabolic syndrome( MS) in the liver. Besides glucose and lipid metabolic disorders,the level of serum uric acid( SUA) is also associated with the progression of NAFLD. This article reviews the research achievements in the association between SUA and NAFLD and points out that SUA can independently predict the risks of MS,type 2 diabetes,and cardiovascular disease in both healthy people and patients. Its mechanism may be that SUA increases the expression of reactive oxygen species( ROS) / thioredoxin- interacting protein( TXNIP) through inducing ROS,and then it activates the NLR pyrin domain containing 3 inflammasome and induces the secretion of interleukin. Both basic and clinical research show that the drugs reducing SUA can inhibit the TXNIP pathway,reduce the blood glucose level,and alleviate liver ROS,inflammation,steatosis,and fibrosis. This article suggests that SUA may be a promising therapeutic method for NAFLD and needs further basic and clinical research.
- fatty liver /
- uric acid /
- metabolic syndrome X

HTML全文

参考文献(32)

[1]AMARAPURKAR DN,HASHIMOTO E,LESMANA LA,et al.How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?[J].J Gastroenterol Hepatol,2007,22(6):788-793.

[2]TARGHER G,DAY CP,BONORA E.Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J].N Engl J Med,2010,363(14):1341-1350.

[3]BALDWIN W,MCRAE S,MAREK G,et al.Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J].Diabetes,2011,60(4):1258-1269.

[4]NAKAHARA T,HYOGO H,YONEDA M,et al.Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients[J].J Gastroenterol,2014,49(11):1477-1484.

[5]LI C,HSIEH MC,CHANG SJ.Metabolic syndrome,diabetes,and hyperuricemia[J].Curr Opin Rheumatol,2013,25(2):210-216.

[6]CHOI HK,FORD ES.Prevalence of the metabolic syndrome in individuals with hyperuricemia[J].Am J Med,2007,120(5):442-447.

[7]MANGGE H,ZELZER S,PUERSTNER P,et al.Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults[J].Obesity(Silver Spring),2013,21(1):e71-e77.

[8]EDWARDS NL.The role of hyperuricemia in vascular disorders[J].Curr Opin Rheumatol,2009,21(2):132-137.

[9]SHORT RA,JOHNSON RJ,TUTTLE KR.Uric acid,microalbuminuria and cardiovascular events in high-risk patients[J].Am J Nephrol,2005,25(1):36-44.

[10]TSOULI SG,LIBEROPOULOS EN,MIKHAILIDIS DP,et al.Elevated serum uric acid levels in metabolic syndrome:an active component or an innocent bystander?[J].Metabolism,2006,55(10):1293-1301.

[11]SHIH MH,LAZO M,LIU SH,et al.Association between serum uric acid and nonalcoholic fatty liver disease in the US population[J].J Formos Med Assoc,2015,114(4):314-320.

[12]XU CF,YU CH,XU L,et al.Hypouricemic therapy:a novel potential therapeutic option for nonalcoholic fatty liver disease[J].Hepatology,2010,52(5):1865-1866.

[13]LIANG J,PEI Y,GONG Y,et al.Serum uric acid and non-alcoholic fatty liver disease in non-hypertensive Chinese adults:the Cardiometabolic Risk in Chinese(CRC)study[J].Eur Rev Med Pharmacol Sci,2015,19(2):305-311.

[14]PEREZ-RUIZ F,ANIEL-QUIROGA MA,HERRERO-BEITES AM,et al.Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients[J].Rheumatol Int,2015,35(9):1519-1524.

[15]ESSAWY SS,ABDEL-SATER KA,ELBAZ AA.Comparing the effects of inorganic nitrate and allopurinol in renovascular complications of metabolic syndrome in rats:role of nitric oxide and uric acid[J].Arch Med Sci,2014,10(3):537-545.

[16]SZABO G,PETRASEK J.Inflammasome activation and function in liver disease[J].Nat Rev Gastroenterol Hepatol,2015,12(7):387-400.

[17]ZHANG X,ZHANG JH,CHEN XY,et al.Reactive oxygen speciesinduced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation[J].Antioxid Redox Signal,2015,22(10):848-870.

[18]SCHRODER K,ZHOU R,TSCHOPP J.The NLRP3 inflammasome:a sensor for metabolic danger?[J].Science,2010,327(5963):296-300.

[19]WANG W,WANG C,DING XQ,et al.Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats[J].Br J Pharmacol,2013,169(6):1352-1371.

[20]XU C,WAN X,XU L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:one stone hits two birds[J].J Hepatol,2015,62(6):1412-1419.

[21]NAKATSU Y,SENO Y,KUSHIYAMA A,et al.The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model[J].Am J Physiol Gastrointest Liver Physiol,2015,309(1):g42-g51.

[22]LONARDO A,LORIA P,LEONARDI F,et al.Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease.A case-control study[J].Dig Liver Dis,2002,34(3):204-211.

[23]SUN DQ,WU SJ,LIU WY,et al.Serum uric acid:a new therapeutic target for nonalcoholic fatty liver disease[J].Expert Opin Ther Targets,2016,20(3):375-387.

[24]YUAN H,YU C,LI X,et al.Serum uric acid levels and risk of metabolic syndrome:a dose-response Meta-analysis of prospective studies[J].J Clin Endocrinol Metab,2015,100(11):4198-4207.

[25]LIU Z,QUE S,ZHOU L,et al.Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence:a Meta-analysis of prospective studies[J].Sci Rep,2015,5:14325.

[26]LI Y,XU C,YU C,et al.Association of serum uric acid level with non-alcoholic fatty liver disease:a cross-sectional study[J].J Hepatol,2009,50(5):1029-1034.

[27]XU C,YU C,XU L,et al.High serum uric acid increases the risk for nonalcoholic fatty liver disease:a prospective observational study[J].PLo S One,2010,5(7):e11578.

[28]SIROTA JC,MCFANN K,TARGHER G,et al.Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States:liver ultrasound data from the National Health and Nutrition Examination Survey[J].Metabolism,2013,62(3):392-399.

[29]WU SJ,ZHU GQ,YE BZ,et al.Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults:a large population-based study[J].Medicine(Baltimore),2015,94(17):e802.

[30]SERTOGLU E,ERCIN CN,CELEBI G,et al.The relationship of serum uric acid with non-alcoholic fatty liver disease[J].Clin Biochem,2014,47(6):383-388.

[31]CARDOSO AS,GONZAGA NC,MEDEIROS CC,et al.Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents[J].J Pediatr(Rio J),2013,89(4):412-418.

[32]SUNDY JS,BARAF HS,YOOD RA,et al.Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment:two randomized controlled trials[J].JAMA,2011,306(7):711-720.

施引文献

资源附件(0)

访问统计